Thiazolidinediones (TZDs) are synthetic ligands (potent activators of PPARγ) that have been used in treating type 2 diabetes but were finally withdrawn due to critical cardiovascular diseases and bladder cancers as side effects [15]. Here, PPARG is linked to cardiovascular disorder.